TIDMEVG

RNS Number : 0732D

Evgen Pharma PLC

19 June 2023

Evgen Pharma plc

("Evgen" or "the Company" or "the Group")

Evgen receives notification of grant success in the Netherlands

for Glioblastoma Pre-clinical and Clinical Studies

Grant provides non-dilutive funding for SFX-01 in glioblastoma

19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the Company's collaborator at The Erasmus University Medical Center, Rotterdam, NL has received a successful notice of a grant for Investigator Sponsored pre-clinical and clinical studies of SFX-01 in glioblastoma. The grant was awarded by KWF Dutch Cancer Society.

The studies funded by the grant will cover use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS) window-of-opportunity study in glioblastoma patients, to establish presence of the drug in human brain tumours and engagement with relevant molecular targets in excised tumour tissue. The work will be conducted by, in the laboratory and clinic of, Dr Marjolein Geurts, neurologist at Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Dr Huw Jones, CEO of Evgen Pharma said:

"We announced earlier this year that our glioblastoma programme would be conducted as an ISS with non-dilutive funding. This award means that we remain on schedule to deliver this study in close collaboration with Dr Geurts. Congratulations to her and the Evgen team who compiled the grant application. The non-dilutive funding enables us to continue to preserve our capital and maintain our cash runway to the end of 2024 whilst continuing to generate valuable data on SFX-01. If the ISS and subsequent clinical trials succeed, SFX-01 will represent a novel and well tolerated option for patients with this devastating disease."

Enquiries:

 
 Evgen Pharma plc                        Tel: +44 207 457 2020 
  Dr Huw Jones, CEO                        enquiries@evgen.com 
  Richard Moulson, CFO 
 FinnCap (Nominated Advisor and          Tel: +44 20 7220 0500 
  Broker) 
  Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
  Alice Lane/Nigel Birks (ECM) 
 Instinctif Partners                     Tel: +44 207 457 2020 
  Melanie Toyne-Sewell / Rozi Morris      Evgen@Instinctif.com 
  / Adam Loudon

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. With respect to areas outside of oncology and inflammation, Evgen signed an out-licensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex(R) technology. More recently Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESFLFVVRDITLIV

(END) Dow Jones Newswires

June 19, 2023 02:00 ET (06:00 GMT)

Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Evgen Pharma.
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Evgen Pharma.